Clinical Trial

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Study acronym: REDUCy
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical HSCT for the treatment of a hematological malignancy, two years after HSCT.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-18.
Trial Details
NCT Number NCT07193420
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions GVHD - Graft-Versus-Host Disease, HSCT, Haploidentical Stem Cell Transplantation
Enrollment 180 participants
Start Date 2026-06
Primary Completion 2030-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-12